^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
SOPHiA DDM Dx RNAtarget Oncology Solution

Type:
CE Marked
Related tests:

Details

Evidence
The CE-IVD marked SOPHiA DDM Dx RNAtarget Oncology Solution accurately detects novel (partner-agnostic) fusions in 11 driver genes and exon-skipping events in EGFR and MET, even with minimal RNA sample input. The solution is expertly designed to detect fusion and exon-skipping events with high diagnostic sensitivity and specificity, delivering clinical-grade analytical performance.
Cancer:
Lung Cancer
Gene:
ALK (Anaplastic lymphoma kinase), EGFR (Epidermal growth factor receptor), FGFR1 (Fibroblast growth factor receptor 1), FGFR2 (Fibroblast growth factor receptor 2), FGFR3 (Fibroblast growth factor receptor 3), FGFR4 (Fibroblast growth factor receptor 4)
See More ...
Method:
Next-Generation Sequencing (NGS)